Paper 78 - A MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF INTRATUMORAL INT230-6 (SHAO, VINBLASTINE, CISPLATIN) COMPARED TO STANDARD OF CARE THERAPY IN SELECTED METASTATIC SOFT TISSUE SARCOMAS: INVINCIBLE-3 TRIAL.

Author(s)

• AA

  Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI

  Toronto Sarcoma Program, Princess Margaret Cancer Center
  Toronto, Ontario, Canada

  Slides

Presenter(s)

• CM

  Christian F. Meyer, MD PhD (he/him/his)

  Assistant Professor/Clinical Associate
  John Hopkins
  Baltimore, Maryland, United States

  Slides

Co-Author(s)

• 

  Lewis H. Bender, MS, MA, MBA (he/him/his)

  Founder, Chairman, CSO, President & CEO
  Intensity Therapeutics
  Shelton, Connecticut, United States
• 

  Kimberly A. Guedes

  Vice President Clinical Operations
  Intensity Therapeutics
  Shelton, Connecticut, United States
• BS

  Brian E. Schwartz, n/a

  Intensity Therapeutics
  Shelton, Connecticut, United States